Cunha Burke A
Infectious Disease Division, Winthrop-University Hospital, Mineola, NY 11501, USA.
Semin Respir Infect. 2002 Sep;17(3):250-8. doi: 10.1053/srin.2002.34692.
Antibiotic resistance is becoming a worldwide concern. Antibiotic resistance may be caused by sporadic mutations, which are not important unless spread clonally. Clonal resistance may disseminate a highly resistant clone to widespread geographic areas. The most effective interventions to limit the clonal spread of resistant organisms are effective infection control measures. Hospital antibiotic formulary restriction is the only control measure with proven effectiveness to control resistance related to antibiotic use. Hospital formularies should eliminate or restrict antibiotics with a high-resistance potential (eg, ceftazidime, ciprofloxacin, and imipenem), and should be replaced with equivalent antibiotics with a low-resistance potential (eg, cefe-pime, levofloxacin, and meropenem). Such low-resistance-potential antibiotics can either prevent or eliminate resistance problems associated with Klebsiella pneumoniae, Enterobacter species, or Pseudomonas aeruginosa. High-resistance-potential antibiotics, particularly ciprofloxacin and ceftazidime, also may indirectly increase the prevalence of highly resistant organisms (eg, methicillin-resistant Staphylococcus aureus [MRSA], vancomycin-resistant enterococci [VRE]). Vancomycin use should be restricted, not because it increases enterococcal resistance per se, but because it selects out naturally resistant enterococcal strains (eg, Enterococcus faecium that are vancomycin resistant). Linezolid does not increase the prevalence of VRE. Clinicians in the outpatient setting should also preferentially use oral antibiotics with a low-resistance potential (eg, clindamycin, metronidazole, doxycycline, minocycline, fluoroquinolones except ciprofloxacin, linezolid, and oral cephalosporins) in preference to their high-resistance-potential counterparts. For antibiotic resistance control interventions to be effective, they must be applied simultaneously to all antibiotics with activity against the specific resistance pathogen at the hospital formulary level. Multiple antibiotic substitutions are usually necessary to eradicate resistance problems caused by a particular pathogen. Multiple drugs of the same spectrum and low-resistance potential are necessary to eliminate resistance problems; single antibiotic substitutions are not effective.
抗生素耐药性正成为一个全球关注的问题。抗生素耐药性可能由散发性突变引起,除非以克隆方式传播,否则这些突变并不重要。克隆耐药性可能会将高度耐药的克隆传播到广泛的地理区域。限制耐药生物体克隆传播的最有效干预措施是有效的感染控制措施。医院抗生素处方限制是唯一已证实对控制与抗生素使用相关的耐药性有效的控制措施。医院处方集应淘汰或限制具有高耐药潜力的抗生素(如头孢他啶、环丙沙星和亚胺培南),并用具有低耐药潜力的等效抗生素(如头孢吡肟、左氧氟沙星和美罗培南)替代。此类低耐药潜力抗生素可预防或消除与肺炎克雷伯菌、肠杆菌属或铜绿假单胞菌相关的耐药问题。高耐药潜力抗生素,尤其是环丙沙星和头孢他啶,也可能间接增加高度耐药生物体(如耐甲氧西林金黄色葡萄球菌[MRSA]、万古霉素耐药肠球菌[VRE])的流行率。万古霉素的使用应受到限制,不是因为它本身会增加肠球菌耐药性,而是因为它会筛选出天然耐药的肠球菌菌株(如耐万古霉素的粪肠球菌)。利奈唑胺不会增加VRE的流行率。门诊环境中的临床医生也应优先使用具有低耐药潜力的口服抗生素(如克林霉素、甲硝唑、多西环素、米诺环素、除环丙沙星外的氟喹诺酮类、利奈唑胺和口服头孢菌素),而不是具有高耐药潜力的同类药物。为使抗生素耐药性控制干预措施有效,必须在医院处方集层面同时应用于所有对特定耐药病原体有活性的抗生素。通常需要进行多种抗生素替代才能根除由特定病原体引起的耐药问题。需要多种相同谱型且低耐药潜力的药物来消除耐药问题;单一抗生素替代无效。